Merck’s Winrevair™ (sotatercept-csrk) earns FDA priority review based on impressive ZENITH trial results
Merck has announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental Biologics License Application (sBLA) for Winrevair (sotatercept-csrk).






















